EP1446008A4 - Compositions and methods for controlled release - Google Patents

Compositions and methods for controlled release

Info

Publication number
EP1446008A4
EP1446008A4 EP02803289A EP02803289A EP1446008A4 EP 1446008 A4 EP1446008 A4 EP 1446008A4 EP 02803289 A EP02803289 A EP 02803289A EP 02803289 A EP02803289 A EP 02803289A EP 1446008 A4 EP1446008 A4 EP 1446008A4
Authority
EP
European Patent Office
Prior art keywords
compositions
methods
controlled release
release
controlled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02803289A
Other languages
German (de)
French (fr)
Other versions
EP1446008A2 (en
Inventor
Arthur H Wong
Jacob M Waugh
Michael D Dake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Essentia Biosystems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentia Biosystems Inc filed Critical Essentia Biosystems Inc
Publication of EP1446008A2 publication Critical patent/EP1446008A2/en
Publication of EP1446008A4 publication Critical patent/EP1446008A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
EP02803289A 2001-10-18 2002-10-17 Compositions and methods for controlled release Withdrawn EP1446008A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33634401P 2001-10-18 2001-10-18
US336344P 2001-10-18
PCT/US2002/033558 WO2003060142A2 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Publications (2)

Publication Number Publication Date
EP1446008A2 EP1446008A2 (en) 2004-08-18
EP1446008A4 true EP1446008A4 (en) 2006-08-16

Family

ID=23315656

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02803289A Withdrawn EP1446008A4 (en) 2001-10-18 2002-10-17 Compositions and methods for controlled release

Country Status (5)

Country Link
EP (1) EP1446008A4 (en)
JP (1) JP2005523890A (en)
AU (1) AU2002365136A1 (en)
CA (1) CA2464131A1 (en)
WO (1) WO2003060142A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145813A1 (en) 2008-03-04 2009-12-03 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
CN102482457B (en) 2009-09-09 2015-04-15 Qd视光有限公司 Particles including nanoparticles, uses thereof, and methods
WO2011031876A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations including nanoparticles
DE102009058769A1 (en) * 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperature-dependent activation of catalytic nucleic acids for controlled drug release
JP2016183434A (en) * 2015-03-26 2016-10-20 国立大学法人京都大学 Surface modification substrate

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US5985554A (en) * 1994-11-02 1999-11-16 Takeda Chemical Industries, Ltd. Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides
WO2001024775A1 (en) * 1999-10-01 2001-04-12 Essentia Biosystems, Inc. Gel-forming compositions
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
US6333194B1 (en) * 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2003024455A2 (en) * 2001-09-17 2003-03-27 Control Delivery Systems, Inc. Stent coated with a sustained-release drug delivery and method for use thereof
WO2003030943A1 (en) * 2001-10-09 2003-04-17 The University Of British Columbia Compositions comprising hydroxyapatite useful for the administration of therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3363399A (en) * 1998-03-27 1999-10-18 President And Fellows Of Harvard College Aptamer based bacterial inhibition systems (abbis)

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985554A (en) * 1994-11-02 1999-11-16 Takeda Chemical Industries, Ltd. Method of probing the function of proteins or peptides encoded by partially sequenced cDNAs by inhibiting protein synthesis with antisense oligonucleotides
WO1998052614A2 (en) * 1997-05-21 1998-11-26 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6333194B1 (en) * 1999-01-19 2001-12-25 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6232068B1 (en) * 1999-01-22 2001-05-15 Rosetta Inpharmatics, Inc. Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
WO2001024775A1 (en) * 1999-10-01 2001-04-12 Essentia Biosystems, Inc. Gel-forming compositions
WO2003024455A2 (en) * 2001-09-17 2003-03-27 Control Delivery Systems, Inc. Stent coated with a sustained-release drug delivery and method for use thereof
WO2003030943A1 (en) * 2001-10-09 2003-04-17 The University Of British Columbia Compositions comprising hydroxyapatite useful for the administration of therapeutic agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIGGINS J B ET AL: "A continuous assay for DNA cleavage: the application of break lights to enediynes, iron-dependent agents, and nucleases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 97, no. 25, 5 December 2000 (2000-12-05), pages 13537 - 13542, XP001094000, ISSN: 0027-8424 *
CASSIDY R A ET AL: "Triplex formation by psoralen-conjugated chimeric oligonucleoside methylphosphonates", BIOCHEMISTRY 25 JUL 2000 UNITED STATES, vol. 39, no. 29, 25 July 2000 (2000-07-25), pages 8683 - 8691, XP002355044, ISSN: 0006-2960 *
MIYASHIRO H ET AL: "Analysis of the RNase H activity by fluorescence resonance energy transfer.", NUCLEIC ACIDS SYMPOSIUM SERIES. 2000, no. 44, 2000, pages 55 - 56, XP002377139, ISSN: 0261-3166 *
SOHAIL M ET AL: "Antisense arrays", MOLECULAR CELL BIOLOGY RESEARCH COMMUNICATIONS, vol. 3, no. 2, February 2000 (2000-02-01), pages 67 - 72, XP002377138, ISSN: 1522-4724 *

Also Published As

Publication number Publication date
AU2002365136A8 (en) 2003-07-30
WO2003060142A2 (en) 2003-07-24
EP1446008A2 (en) 2004-08-18
CA2464131A1 (en) 2003-07-24
AU2002365136A1 (en) 2003-07-30
WO2003060142A9 (en) 2003-08-21
JP2005523890A (en) 2005-08-11
WO2003060142A3 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
GB0218157D0 (en) Compositions for controlled release
AU2002357119A8 (en) Mitocidal compositions and methods
AU2002300377A1 (en) Compositions for controlled release
TWI347202B (en) Controlled release preparation
IL173300A0 (en) Compositions for encapsulation and controlled release
EP1423120A4 (en) 2h-phthalazin-1-ones and methods for use thereof
HUP0301591A3 (en) Controlled release hydrocodone compositions
HK1085387A1 (en) Controlled release depot formulations
IL186782A0 (en) Controlled release composition and method of producing the same
SG84623A1 (en) Controlled release compositions
EP1434772A4 (en) Compounds and methods
EP1476067A4 (en) Novel compositions and methods for cancer
EP1509539A4 (en) Novel compositions and methods for cancer
AU2002357748A8 (en) Osteopontin-related compositions and methods
EP1501352A4 (en) Methods and compositions for controlled release of drugs
EP1469769A4 (en) Novel compositions and methods for cancer
PL364570A1 (en) Composition and method for controlled release injections
AU2002359694A8 (en) Compounds and methods
AU2002365136A8 (en) Compositions and methods for controlled release
EP1469870A4 (en) Novel compositions and methods for cancer
AU2003212866A1 (en) Controlled release compositions and methods for using same
EP1379240A4 (en) Compounds and methods
AU2002359869A8 (en) Pak5-related compositions and methods
GB0107033D0 (en) Method and composition
GB0111389D0 (en) Controlled release formulations

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040517

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1067848

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/58 20060101ALI20060704BHEP

Ipc: C12Q 1/68 20060101ALI20060704BHEP

Ipc: C07H 21/04 20060101ALI20060704BHEP

Ipc: C07H 21/02 20060101ALI20060704BHEP

Ipc: C07H 21/00 20060101ALI20060704BHEP

Ipc: A01N 43/04 20060101ALI20060704BHEP

Ipc: A01N 37/18 20060101ALI20060704BHEP

Ipc: C12Q 1/34 20060101AFI20060704BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20060714

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVANCE THERAPEUTICS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: REVANCE THERAPEUTICS, INC.

17Q First examination report despatched

Effective date: 20070326

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DAKE, MICHAEL, D.

Inventor name: WAUGH, JACOB, M.

Inventor name: WONG, ARTHUR, H.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090501

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1067848

Country of ref document: HK